We have developed a single process for producing two key COVID-19 vaccine antigens:
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are …

Vaccine design strategies against severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) are focused on the Spike protein or its subunits as the main antigen target of …

Background Developing effective vaccines against SARS-CoV-2 that consider
manufacturing limitations, equitable access, and acceptance is necessary for developing …

The novel coronavirus pneumonia (COVID-19) pandemic is a great threat to human society
and now is still spreading. Although several vaccines have been authorized for emergency …

The receptor binding domain (RBD) of the SARS‐CoV‐2 spike (S)‐protein is a prime target
of virus‐neutralizing antibodies present in convalescent sera of COVID‐19 patients and thus …

Abstract A SARS-CoV-2 RBD219-N1C1 (RBD219-N1C1) recombinant protein antigen
formulated on Alhydrogel® has recently been shown to elicit a robust neutralizing antibody …

Developing affordable and easily manufactured SARS-CoV-2 vaccines will be essential to
achieve worldwide vaccine coverage and long-term control of the COVID-19 pandemic …

In the context of the COVID-19 pandemic, conducting antibody testing and vaccination is
critical. In particular, the continued evolution of SARS-CoV-2 raises concerns about the …

SARS-CoV-2 protein subunit vaccines are currently being evaluated by multiple
manufacturers to address the global vaccine equity gap, and need for low-cost, easy to …

The unprecedented global impact caused by SARS-CoV-2 imposed huge health and
economic challenges, highlighting the urgent need for safe and effective vaccines. The …